ADMA Biologics, Inc. 8-K Report: Key Updates on December 30, 2024
Based on the provided section of the financial report, here are the key pieces of information and insights extracted:
- Entity Information:
- Company Name: ADMA Biologics, Inc.
- CIK (Central Index Key): 0001368514
- State of Incorporation: Delaware (DE)
- SEC File Number: 001-36728
- EIN (Employer Identification Number): 56-2590442
- Address: 465 State Route 17, Ramsey, NJ 07446
- Contact Number: 201-478-5552
- Filing Details:
- Filing Type: 8-K (Current Report)
- Filing Date: December 30, 2024
- Stock Information:
- Common Stock Symbol: ADMA
- Exchange: NASDAQ
- Date Context:
- Reporting Period: The report pertains to a single day, December 30, 2024.
Insights:
- The filing indicates that ADMA Biologics, Inc. is reporting significant information on a specific date, which could relate to a material event affecting operations or financial position, as is typical for an 8-K filing.
- This report is structured in XBRL (eXtensible Business Reporting Language), which is standard for SEC filings, allowing for better data extraction and analysis.
- The company operates in the biotech sector, which may imply a focus on research and development, regulatory approvals, and product announcements. The timing of the report could suggest an important development in these areas.
Considerations:
- Given that it is an 8-K filing, stakeholders should examine the attached details for specifics on the event being reported, such as acquisitions, financial results, changes in management, or other significant events that could impact shareholder value and market perceptions.